Featured 13F manager
Farallon Capital Management, L.l.c.
San Francisco, CA 87 processed 13Fs on this site · 2021 Q3–2026 Q2
- $21.7B
- 77 Positions
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
Portfolio
top 5 29.9% · top 10 44.0%
- RVMD - Revolution Medicines 11.7%
- EA - Electronic Arts 7.5%
- BBIO - Bridgebio Pharma 3.7%
- PTGX - Protagonist Therapeutics 3.6%
- EXEL - Exelixis 3.4%
- LQDA - Liquidia 3.1%
- AMZN - Amazon 2.9%
- LNTH - Lantheus 2.9%
- NTRA - Natera 2.8%
- UNH - Unitedhealth Group 2.4%
- TMO - Thermo Fisher Scientific 2.4%
- ROIV - Roivant Sciences 2.3%
- Other 51.3%
AUM over time
Book
| Activision Blizzard | 9.54% | New | 20,320,000 | $93.63 | $1.9B | +20,320,000 | +$1.9B |
| Horizon Therapeutics Pub L | 3.86% | New | 6,656,823 | $115.69 | $770M | +6,656,823 | +$770M |
| UNH - Unitedhealth Group | 3.40% | Add +7.0% | 1,346,700 | $504.19 | $679M | +87,900 | +$74M |
| TRU - Transunion | 3.32% | Reduce −1.0% | 9,233,256 | $71.79 | $663M | −91,537 | −$68M |
| EXEL - Exelixis | 2.83% | Hold | 25,860,000 | $21.85 | $565M | — | — |
| IQV - IQVIA | 2.73% | Reduce −28.5% | 2,766,332 | $196.75 | $544M | −1,100,780 | −$325M |
| TMO - Thermo Fisher Scientific | 2.66% | Reduce −15.8% | 1,047,531 | $506.17 | $530M | −196,128 | −$119M |
| CRM - Salesforce | 2.57% | Add +29.9% | 2,525,638 | $202.78 | $512M | +581,300 | +$101M |
| CHTR - Charter Communications · CL A | 2.45% | New | 1,111,341 | $439.82 | $489M | +1,111,341 | +$489M |
| GOOG - Alphabet · CL C | 2.35% | Reduce −6.4% | 3,557,140 | $131.85 | $469M | −245,000 | +$9M |
| MSFT - Microsoft | 2.14% | Add +56.7% | 1,349,178 | $315.75 | $426M | +488,000 | +$133M |
| ARMK - Aramark | 2.11% | Add +11.5% | 12,136,200 | $34.70 | $421M | +1,249,316 | −$48M |
| AZNN — | 2.06% | Hold | 6,059,553 | $67.72 | $410M | — | — |
| SPGI - S&P Global | 1.83% | Reduce −8.0% | 999,395 | $365.41 | $365M | −86,900 | −$70M |
| WAB - Wabtec | 1.73% | Add +0.4% | 3,256,047 | $106.27 | $346M | +14,117 | −$10M |
| ADI - Analog Devices | 1.70% | Reduce −6.4% | 1,942,000 | $175.09 | $340M | −133,000 | −$64M |
| CBRE - CBRE Group · CL A | 1.67% | New | 4,520,388 | $73.86 | $334M | +4,520,388 | +$334M |
| NYT - New York Times · CL A | 1.64% | Hold | 7,964,791 | $41.20 | $328M | — | — |
| CNC - Centene Del | 1.53% | Reduce −6.0% | 4,445,075 | $68.88 | $306M | −284,000 | −$13M |
| INTU - Intuit | 1.42% | Reduce −19.6% | 556,100 | $510.94 | $284M | −135,200 | −$33M |
| YMM - Full Truck Alliance | 1.35% | Reduce −16.7% | 38,190,495 | $7.04 | $269M | −7,667,743 | −$16M |
| SHW - Sherwin Williams | 1.34% | Reduce −23.9% | 1,046,792 | $255.05 | $267M | −328,600 | −$98M |
| NOW - Servicenow | 1.34% | Reduce −3.9% | 477,550 | $558.96 | $267M | −19,500 | −$12M |
| BSX - Boston Scientific | 1.33% | Reduce −0.1% | 5,039,257 | $52.80 | $266M | −6,000 | −$7M |
| MA - Mastercard · CL A | 1.20% | Reduce −22.7% | 606,471 | $395.91 | $240M | −178,300 | −$69M |
| BX - Blackstone | 1.20% | Reduce −27.2% | 2,227,051 | $107.14 | $239M | −831,200 | −$46M |
| HWM - Howmet Aerospace | 1.10% | Reduce −18.9% | 4,747,627 | $46.25 | $220M | −1,110,000 | −$71M |
| AON - AON PLC · CL A | 1.08% | Reduce −19.6% | 665,661 | $324.22 | $216M | −162,125 | −$70M |
| CSGP - Costar Group | 1.07% | Add +1.3% | 2,786,856 | $76.89 | $214M | +35,800 | −$31M |
| HUM - Humana | 0.89% | Add +41.0% | 364,461 | $486.52 | $177M | +106,000 | +$62M |
| V - VISA · CL A | 0.88% | Reduce −26.7% | 761,410 | $230.01 | $175M | −277,900 | −$72M |
| Sarepta Therapeutics | 0.84% | Add +14.1% | 1,375,200 | $121.22 | $167M | +170,000 | +$29M |
| ELV - Elevance Health | 0.83% | Reduce −14.4% | 381,330 | $435.42 | $166M | −64,000 | −$32M |
| LNTH - Lantheus | 0.56% | Add +17.5% | 1,598,500 | $69.48 | $111M | +238,000 | −$3M |
| BEAM - Beam Therapeutics | 0.54% | Add +30.2% | 4,481,839 | $24.05 | $108M | +1,040,317 | −$2M |
| CI - The Cigna Group | 0.52% | Add +67.9% | 366,000 | $286.07 | $105M | +148,000 | +$44M |
| XYZ - Block · CL A | 0.52% | Reduce −30.1% | 2,336,350 | $44.26 | $103M | −1,007,700 | −$119M |
| NTRA - Natera | 0.51% | Add +72.0% | 2,277,883 | $44.25 | $101M | +953,700 | +$36M |
| RVMD - Revolution Medicines | 0.46% | Add +19.5% | 3,325,480 | $27.68 | $92M | +542,000 | +$18M |
| PTGX - Protagonist Therapeutics | 0.46% | Add +20.7% | 5,446,430 | $16.68 | $91M | +935,000 | −$34M |
| PACB — | 0.43% | Add +22.6% | 10,224,120 | $8.35 | $85M | +1,886,000 | −$26M |
| INSP - Inspire Med Sys | 0.42% | Add +31.9% | 426,096 | $198.44 | $85M | +103,000 | −$20M |
| BABA - Alibaba Group | 0.37% | Reduce −53.9% | 862,233 | $86.74 | $75M | −1,007,767 | −$81M |
| BEKE - KE | 0.37% | Hold | 4,758,500 | $15.52 | $74M | — | — |
| VRTX - Vertex Pharmaceuticals | 0.35% | New | 202,000 | $347.74 | $70M | +202,000 | +$70M |
| PCG - Pg And E | 0.34% | Reduce −15.7% | 4,221,642 | $16.13 | $68M | −783,500 | −$18M |
| AGIO - Agios Pharmaceuticals | 0.34% | Add +2.3% | 2,750,829 | $24.75 | $68M | +62,000 | −$8M |
| THC - Tenet Healthcare | 0.34% | Add +37.0% | 1,030,000 | $65.89 | $68M | +278,000 | +$7M |
| SIMO - Silicon Motion Technology | 0.27% | New | 1,045,000 | $51.25 | $54M | +1,045,000 | +$54M |
| EVH - Evolent Health · CL A | 0.26% | Hold | 1,900,909 | $27.23 | $52M | — | — |
| DXCM - Dexcom | 0.25% | New | 544,000 | $93.30 | $51M | +544,000 | +$51M |
| NBIX - Neurocrine Biosciences | 0.25% | New | 448,000 | $112.50 | $50M | +448,000 | +$50M |
| ROIV - Roivant Sciences | 0.23% | Add +63.6% | 3,853,400 | $11.68 | $45M | +1,498,400 | +$21M |
| Mirati Therapeutics | 0.22% | New | 1,001,000 | $43.56 | $44M | +1,001,000 | +$44M |
| HCA - Hca Healthcare | 0.22% | Reduce −33.5% | 174,400 | $245.98 | $43M | −88,000 | −$37M |
| Denbury | 0.21% | New | 425,000 | $98.01 | $42M | +425,000 | +$42M |
| Savara | 0.21% | Hold | 10,908,086 | $3.78 | $41M | — | — |
| IONS - Ionis Pharmaceuticals | 0.17% | Add +14440.0% | 727,000 | $45.36 | $33M | +722,000 | +$33M |
| CRL - Charles Riv Labs Intl | 0.14% | New | 146,000 | $195.98 | $29M | +146,000 | +$29M |
| OPCH - Option Care Health | 0.14% | Reduce −58.3% | 862,000 | $32.35 | $28M | −1,205,134 | −$39M |
| ENTA - Enanta Pharmaceuticals | 0.10% | Hold | 1,875,000 | $11.17 | $21M | — | — |
| United States Stl | 0.10% | New | 635,000 | $32.48 | $21M | +635,000 | +$21M |
| Masimo | 0.10% | Reduce −38.1% | 227,649 | $87.68 | $20M | −140,000 | −$41M |
| BHVN - Biohaven | 0.10% | Hold | 750,000 | $26.01 | $20M | — | — |
| IMVT - Immunovant | 0.10% | New | 504,000 | $38.39 | $19M | +504,000 | +$19M |
| Sdcl Edge Acquisition · CL A | 0.09% | Hold | 1,732,500 | $10.60 | $18M | — | — |
| National Instrs | 0.08% | New | 265,000 | $59.62 | $16M | +265,000 | +$16M |
| Ares Acquisition · CL A | 0.08% | Hold | 1,425,000 | $10.76 | $15M | — | — |
| Zymeworks | 0.06% | Hold | 2,000,000 | $6.34 | $13M | — | — |
| Earthstone Energy · CL A | 0.06% | New | 618,831 | $20.24 | $13M | +618,831 | +$13M |
| TAL - Tal Education Group | 0.06% | New | 1,365,000 | $9.11 | $12M | +1,365,000 | +$12M |
| SLNOEUR - Soleno Therapeutics | 0.06% | New | 388,000 | $29.51 | $11M | +388,000 | +$11M |
| Chindata Group | 0.05% | New | 1,300,000 | $8.30 | $11M | +1,300,000 | +$11M |
| CRNX — | 0.05% | New | 361,904 | $29.74 | $11M | +361,904 | +$11M |
| Screaming Eagle Acquisitn · CLASS A | 0.05% | Hold | 1,000,000 | $10.46 | $10M | — | — |
| VYGR - Voyager Therapeutics | 0.05% | Hold | 1,292,000 | $7.75 | $10M | — | — |
| AXSM - Axsome Therapeutics | 0.04% | Reduce −53.9% | 125,653 | $69.89 | $9M | −147,147 | −$11M |
| RIO - Rio Tinto | 0.04% | Hold | 137,500 | $63.64 | $9M | — | — |
| Holding | 0.04% | Add +56.1% | 1,560,500 | $5.56 | $9M | +560,500 | +$1M |
| APLSUSD - Apellis Pharmaceuticals | 0.04% | Add +384.5% | 194,053 | $38.04 | $7M | +154,000 | +$4M |
| SLAM · CL A | 0.03% | Hold | 570,396 | $10.78 | $6M | — | — |
| VNET - VNET Group | 0.03% | Hold | 1,775,000 | $3.13 | $6M | — | — |
| Gores Ix · CLASS A | 0.03% | Hold | 500,000 | $10.39 | $5M | — | — |
| Gossamer Bio | 0.03% | New | 6,130,272 | $0.8328 | $5M | +6,130,272 | +$5M |
| NDAQ - Nasdaq | 0.02% | New | 102,500 | $48.59 | $5M | +102,500 | +$5M |
| Holding · CL A | 0.02% | Hold | 400,000 | $10.38 | $4M | — | — |
| Swiftmerge Acquisition · CLASS A | 0.02% | Hold | 300,000 | $10.63 | $3M | — | — |
| Berenson Acquisition I · CL A | 0.01% | Hold | 285,715 | $10.37 | $3M | — | — |
| Verve Therapeutics | 0.01% | New | 211,293 | $13.26 | $3M | +211,293 | +$3M |
| Cara Therapeutics | 0.01% | Hold | 1,666,591 | $1.68 | $3M | — | — |
| TVTX - Travere Therapeutics | 0.01% | New | 271,517 | $8.94 | $2M | +271,517 | +$2M |
| Arya Sciences Acqu Iv · CL A | 0.01% | Hold | 200,000 | $10.85 | $2M | — | — |
| Marblegate Acquisition · CL A | 0.01% | Hold | 150,000 | $10.44 | $2M | — | — |
| Forte Biosciences | 0.01% | New | 1,810,455 | $0.6620 | $1M | +1,810,455 | +$1M |
| OKLO - Altc Acquisition · CL A | 0.01% | Hold | 98,300 | $10.35 | $1M | — | — |
| Summit Midstream Partners | 0.00% | Hold | 58,214 | $13.85 | $806K | — | — |
| EDU — | 0.00% | Hold | 13,000 | $58.55 | $761K | — | — |
| CYTK - Cytokinetics | 0.00% | Hold | 21,772 | $29.46 | $641K | — | — |
| Lufax · CL A | 0.00% | Reduce −97.0% | 600,000 | $1.06 | $636K | −19,349,819 | −$28M |
| MDGL - Madrigal Pharmaceuticals | 0.00% | Hold | 3,319 | $146.04 | $485K | — | — |
| BNTX - Biontech Se | 0.00% | Hold | 3,844 | $108.64 | $418K | — | — |
| Karuna Therapeutics | 0.00% | Hold | 2,200 | $169.09 | $372K | — | — |
| ALNY - Alnylam Pharmaceuticals | 0.00% | Hold | 2,000 | $177.10 | $354K | — | — |
| EHC - Encompass Health | 0.00% | Reduce −97.0% | 3,000 | $67.16 | $201K | −97,000 | −$7M |
| Blueprint Medicines | 0.00% | Reduce −82.2% | 4,000 | $50.22 | $201K | −18,420 | −$1M |
| R1 Rcm | 0.00% | Reduce −97.8% | 12,000 | $15.07 | $181K | −540,000 | −$10M |
| COGT - Cogent Biosciences | 0.00% | Reduce −98.3% | 17,000 | $9.75 | $166K | −966,452 | −$11M |
Showing top 50 of 107 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| EFX - Equifax | 1.39% | Exit | 0 | $235.30 | $249M | −1,058,697 | −$249M |
| BIIB - Biogen | 0.96% | Exit | 0 | $284.85 | $172M | −604,098 | −$172M |
| Iveric Bio | 0.54% | Exit | 0 | $39.34 | $96M | −2,442,299 | −$96M |
| ARGX - Argenx Se | 0.35% | Exit | 0 | $389.73 | $63M | −161,000 | −$63M |
| Chinook Therapeutics | 0.33% | Exit | 0 | $38.42 | $59M | −1,523,000 | −$59M |
| Exact Sciences | 0.32% | Exit | 0 | $93.90 | $57M | −602,000 | −$57M |
| Aerojet Rocketdyne | 0.29% | Exit | 0 | $54.87 | $53M | −959,378 | −$53M |
| Reata Pharmaceuticals · CL A | 0.26% | Exit | 0 | $101.96 | $46M | −451,700 | −$46M |
| UTHR - United Therapeutics | 0.24% | Exit | 0 | $220.75 | $43M | −193,267 | −$43M |
| Ambrx Biopharma | 0.21% | Exit | 0 | $16.46 | $37M | −2,269,000 | −$37M |
| AIG - American Eqty Invt Life Hld | 0.11% | Exit | 0 | $52.11 | $20M | −383,000 | −$20M |
| Life Storage | 0.07% | Exit | 0 | $132.96 | $12M | −89,794 | −$12M |
| BRKR - Bruker | 0.06% | Exit | 0 | $73.92 | $11M | −150,476 | −$11M |
| Holding · CL A | 0.05% | Exit | 0 | $10.56 | $8M | −775,200 | −$8M |
| Holding · CLASS A | 0.04% | Exit | 0 | $10.35 | $8M | −745,000 | −$8M |
| Corsair Partnering · CL A | 0.04% | Exit | 0 | $10.37 | $7M | −700,000 | −$7M |
| Blue Whale Acquisition · CLASS A | 0.03% | Exit | 0 | $10.15 | $6M | −575,000 | −$6M |
| INTC - Intellia Therapeutics | 0.03% | Exit | 0 | $40.78 | $5M | −116,000 | −$5M |
| Finserv Acquisition Ii · CL A | 0.02% | Exit | 0 | $10.23 | $4M | −400,000 | −$4M |
| Cartica Acquisition · CLASS A | 0.02% | Exit | 0 | $10.67 | $4M | −350,000 | −$4M |
| Uta Acquisition · CLASS A | 0.02% | Exit | 0 | $10.57 | $4M | −344,100 | −$4M |
| ALVO - Alvotech | 0.02% | Exit | 0 | $7.74 | $3M | −437,110 | −$3M |
| Atento S A | 0.01% | Exit | 0 | $0.9998 | $2M | −2,230,357 | −$2M |
| PRVA - Privia Health Group | 0.01% | Exit | 0 | $26.11 | $2M | −74,000 | −$2M |
| ICE - Intercontinental Exchange | 0.01% | Exit | 0 | $113.09 | $1M | −12,786 | −$1M |
| Avrobio | — | Exit | 0 | $0.9503 | $855K | −899,700 | −$855K |
| Better Therapeutics | — | Exit | 0 | $1.08 | $357K | −330,619 | −$357K |
| Clever Leaves | — | Exit | 0 | $0.2025 | $330K | −1,629,363 | −$330K |
| ARWR - Arrowhead Pharmaceuticals | — | Exit | 0 | $35.69 | $207K | −5,800 | −$207K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | new holds | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | new holds | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | new holds | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | new holds | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | new holds | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | new holds | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | new holds | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | new holds | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | new holds | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | new holds | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | new holds | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | new holds | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | new holds | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | new holds | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | new holds | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | new holds | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | new holds | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | new holds | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | new holds | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | new holds | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | new holds | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | new holds | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | new holds | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | new holds | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | new holds | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | new holds | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | new holds | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | new holds | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | new holds | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | new holds | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | new holds | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | new holds | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | new holds | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | new holds | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | new holds | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | new holds | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | new holds | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | new holds | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | new holds | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | new holds | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | new holds | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | new holds | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | new holds | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | new holds | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | new holds | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | new holds | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | new holds | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | new holds | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | new holds | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | new holds | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | new holds | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | new holds | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | new holds | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | new holds | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | new holds | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | new holds | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | new holds | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | new holds | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | new holds | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | new holds | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | new holds | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | new holds | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | new holds | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | new holds | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | new holds | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
FARALLON CAPITAL MANAGEMENT, L.L.C.
87 processed 13Fs on this site · 2021 Q3–2026 Q2